Market Research Logo

Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020

About Chronic Obstructive Pulmonary Disease (COPD)

COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing.

Technavio’s analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck
  • Novartis
  • Teva
Other prominent vendors
  • Ache Laboratorios Farmaceuticos
  • Almirall
  • Aquinox Pharmaceuticals
  • Ario Pharma
  • Asmacure
  • Astellas Pharma
  • BioMarck Pharmaceuticals
  • Chiesi Farmaceutici
  • Cytokinetics
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Innoviva
  • Invion
  • MediciNova
  • Mereo BioPharma
  • Mylan
  • Orion Corporation
  • Palobiofarma
  • Pearl Therapeutics
  • Pharmaxis
  • Prosonix
  • Pulmagen Therapeutics
  • RespiVert
  • SolAeroMed
  • Sunovion Pharmaceuticals
  • Theravance Biopharma
  • Theron Pharmaceuticals
  • Verona Pharma
  • Xention
  • Yungjin Pharm
  • ZAI Lab
Market driver
  • Uptake of LABA/LAMA combination therapies
  • For a full, detailed list, view our report
Market challenge
  • Negligence toward use of controller medications
  • For a full, detailed list, view our report
Market trend
  • Increased adoption of e-cigarettes and smoking cessation products
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global chronic obstructive pulmonary disease (COPD) drugs market: AstraZeneca, Boehringer Ingelheim, Merck, and Novartis.

Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, Chiesi Farmaceutici, Cytokinetics, F. Hoffmann-La Roche, Gilead Sciences, Innoviva, Invion, MediciNova, Mereo BioPharma, Mylan, Orion Corporation, Palobiofarma, Pearl Therapeutics, Pharmaxis, Prosonix, Pulmagen Therapeutics, RespiVert, SolAeroMed, Sunovion Pharmaceuticals, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention , Yungjin Pharm, and ZAI Lab.

Commenting on the report, an analyst from Technavio’s team said: “Innovative technologies for drug delivery will be one of the key trends for market growth. Vendors are investing heavily in R&D activities to design and develop innovative inhalers and nebulizers that are compact, portable, patient-friendly, and provide accurate results. The high efficiency of these devices also helps reduce the residual drug volume in the them when compared to other types of nebulizers. The advances in inhalers such as sensors, and the use of smartphone and tablets that can track and record the drug treatment dose have resulted in providing an interface between the physicians and patients.”

According to the report, increase in smoking prevalence will be the key driver for market growth. Tobacco smoking is considered to be the leading cause of COPD, with 85% of the cases being because of this reason. The other 15% may be due to the exposure to second-hand smoke, air pollution, chest infections, and genetic disorders such as AAT deficiency. Thus, the rising smoking population is expected to increase the number of individuals with COPD, which increases the treatment-seeking population and drives the market

Further, the report states that negligence towards use of controller medications will be a major challenge for the market.

Companies Mentioned

AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, Chiesi Farmaceutici, Cytokinetics, F. Hoffmann-La Roche, Gilead Sciences, Innoviva, Invion, MediciNova, Mereo BioPharma, Mylan, Orion Corporation, Palobiofarma, Pearl Therapeutics, Pharmaxis, Prosonix, Pulmagen Therapeutics, RespiVert, SolAeroMed, Sunovion Pharmaceuticals, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention , Yungjin Pharm, ZAI Lab.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Breakthrough in COPD research
      • Table Breakthrough research activities in field of COPD
    • COPD: An overview
  • Pipeline analysis
    • Table Percentage share of pipeline molecules based on stage of development
    • Table Pipeline molecules based on MOA and stage of development
    • Table Percentage share of pipeline drugs based on MOA
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global COPD drugs market 2015-2020 ($ billions)
      • Table Global COPD drugs market snapshot: Developed and emerging markets 2015
      • Table Global COPD drugs market: Key parameters driving the market 2015
    • Five forces analysis
      • Table Five forces analysis
  • Key buying criteria for COPD drugs
    • Table Key buying criteria for COPD drugs
    • Table Impact of key customer segments on global COPD drugs market
  • Market segmentation by drug class
    • Table Segmentation of COPD drugs based on drug class
    • Table Percentage share of global COPD drugs by drug class based on revenue 2015
    • Table Global COPD drugs market: Drug class segmentation growth cycle analysis 2015
    • Combination therapies
      • Table Combination therapies market in global COPD drugs market 2015-2020 ($ billions)
    • Bronchodilators
      • Table Bronchodilators market in global COPD drugs market 2015-2020 ($ billions)
    • Steroids
      • Table Steroid drugs market in global COPD drugs market 2015-2020 ($ billions)
    • Leukotriene antagonists
      • Table Leukotriene antagonists market in global COPD drugs market 2015-2020 ($ billions)
    • PDE-4 inhibitors
      • Table YoY growth and revenue of Daliresp 2012-2015 ($ billions)
    • Other medications
      • Table Global COPD drugs market segmentation by drug class 2015
  • Segmentation by ROA
    • Table Segmentation of global COPD drugs market by ROA
    • Inhalation
    • Oral
  • Drug delivery devices market for COPD drugs
    • Market overview
      • Table Global COPD drug delivery devices market 2015-2020 ($ millions)
    • Market segmentation by product type
      • Table Global COPD devices market segmentation by product type
      • Table Percentage share of global COPD drug delivery devices by type 2015
      • Table Percentage share of inhalers in global COPD drug delivery devices market 2015
      • Table Inhalers market in global COPD drug-devices market 2015-2020 ($ millions)
      • Table Percentage share of nebulizers in global COPD drug delivery devices market by technology 2015
      • Table Nebulizers market in global COPD drug-devices market 2015-2020 ($ millions)
  • Geographical segmentation
    • Global COPD drugs market by geography 2015-2020
      • Table Global COPD drugs market by geography 2015-2020
      • Table Percentage share of global COPD drugs market by geography 2015 and 2020
      • Table Global COPD drugs market segmentation by geography 2015-2020 ($ billions)
      • Table Global share of COPD drugs market by geography 2015
    • COPD drugs market in Americas
      • Table COPD drugs market in Americas 2015-2020 ($ billions)
    • COPD drugs market in EMEA
      • Table Prevalence rates of COPD in few countries of EMEA
      • Table COPD drugs market in EMEA 2015-2020 ($ billions)
    • COPD drugs market in APAC
      • Table COPD drugs market in APAC 2015-2020 ($ billions)
    • COPD drugs market in China
      • Table COPD drugs market in China 2015-2020 ($ billions)
      • Table Global COPD drugs market: Country analysis based on revenue and growth rate
  • Market drivers
    • Increase in smoking prevalence
    • Uptake of LABA/LAMA combination therapies
    • Robust pipeline with tentative approval of drugs
      • Table Drug approvals in COPD drugs market in past three years (2014-2016)
      • Table Few COPD drug molecules in registration stage
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Lack of innovation in pipeline molecules
    • Negligence toward use of controller medications
      • Table Controller and rescue medications for the treatment of COPD
    • Low diagnosis rates
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Innovative technologies for drug delivery
    • Increased adoption of e-cigarettes and smoking cessation products
    • Emergence of ultrasonic nebulizers
    • Increase in online marketing services
    • Growing use of home healthcare devices
  • Vendor landscape
    • Competitive scenario
      • Table Key vendors ranking 2015
      • Table Market share of key vendors based on revenues 2015
      • Table Geographical presence of key vendors
      • Table Competitive scenario of global COPD drugs market vendors 2015-2020
    • Key news
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions)
      • Table AstraZeneca: Geographical segmentation of Symbicort 2015
      • Table AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions)
      • Table AstraZeneca: Geographical segmentation of Pulmicort 2015
      • Table AstraZeneca: Metrics analysis
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions)
      • Table Boehringer Ingelheim: Metrics analysis
    • GSK
      • Table GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions)
      • Table Geographical segmentation of Seretide/Advair 2015
      • Table GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions)
      • Table GSK: Geographical segmentation of Flixotide/Flovent 2015
      • Table GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions)
      • Table GSK: Geographical segmentation of Ventolin 2015
      • Table GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions)
      • Table GSK: Geographical segmentation of Relvar/Breo Ellipta 2015
      • Table GSK: YoY growth and revenue of Anoro Ellipta 2014-2015 ($ millions)
      • Table GSK: Geographical segmentation of Anoro Ellipta 2015
      • Table GSK: Metrics analysis
    • Novartis
      • Table Novartis: YoY revenue and growth rate of Onbrez Breezhaler/Arcapta Neohaler 2014-2015 ($ millions)
      • Table Novartis: YoY revenue and growth rate of Seebri Breezhaler 2013-2015 ($ millions)
      • Table Novartis: YoY revenue and growth rate of Ultibro Breezhaler 2013-2015 ($ millions)
      • Table Novartis: Metrics analysis
    • Teva Pharmaceuticals
      • Table Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
      • Table Teva Pharmaceuticals: YoY revenue and growth rate of Qvar 2013-2015 ($ millions)
      • Table Teva Pharmaceuticals: Metrics analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report